UB-312 Vaccine Well Tolerated by Healthy Adults in Ongoing Trial
UB-312, an experimental vaccine targeting aggregated and toxic forms of alpha-synuclein to treat Parkinson’s disease, was generally well tolerated at multiple doses in a clinical trial in healthy adults. Study data also suggest that UB-312 prompted an immune response, as designed, against the alpha-synuclein protein. With two doses now selected…